Todor Pichurov

PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) Holds Onto Gains

by Todor Pichurov April 6, 2015

After catching a nice boost on the charts in late March, PharmaCyte Biotech is currently doings its best to hold onto its newfound gains. The stock closed 2% up on Thursday, on above-average volume of 3 million shares.

PMCB is a biopharma stock with a difference. Sadly, the difference is that unlike many other OTC biopharma stocks, PMCB is being hammered by paid pumps non-stop. There have been about 100 pump emails targeting PMCB stock since early January 2015 and the promoters seem to have no intention to stop sending them.

The latest pump is dated April 1 but is no April fool’s joke. Promoter Obitstocks pocketed $5 thousand to tout PMCB. Three other emails, each backed by compensation of $5 thousand were sent on the previous day as well.

PMCB jumped by 28% on March 26. The reason was the publication of one of the so-called ‘research reports’ Goldman Small Cap Research issues. This particular one was focused on PMCB. The report would have carried a lot more weight if its disclaimer did not disclose monetary compensation paid out by an unnamed ‘third party’.

PMCB filed its quarterly a few days later and this is the brief rundown of the numbers in it:

  • $958 thousand in cash
  • $378 thousand in total liabilities
  • zero revenues
  • $1.45 million in quarterly net loss

The company is doing its best to keep investors excited through a constant stream of PR but considering the fact that there has been a three-month-long constant bombardment of pump emails, investors may want to take their time and do more research on this one.

Comments 2

1. Guest
April 06, 2015, 03:31PM

Quotes What are you talking about? Back in the toilet!

2. Guest
April 06, 2015, 09:02AM

Quotes this is complete trash. Who pays you?

Type the characters that you see in the box (5 characters).